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  I
deally, evaluations of strategies 
related to the use of antiretroviral 
agents would use large-scale 
randomized trials with HIV-related 
mortality as the primary endpoint. In 
reality, however, such studies are rarely 
conducted, given the long follow-up 
needed and the substantial costs. 
Furthermore, people currently living 
with HIV/AIDS need treatment now, 
not at the conclusion of long-term 
prospective trials. 
    Model-based methods are a 
powerful and practical means of 
performing formal comparisons 
of health interventions when the 
ideal is not possible. Model-based 
analyses synthesize data from multiple 
sources, permitting decision makers 
to understand the likely impact of 
different strategies and to set priorities 
for clinical trials [1]. Models also offer 
a practical framework for managing 
uncertainty via (1) sensitivity analysis 
(i.e., sensitivity of the model’s outputs 
to variation in the model’s parameters 
that are either variable or estimated 
with uncertainty) and (2) analysis 
of different scenarios (which can 
represent different settings and/or 
different levels of optimism in the 
values of the model’s parameters) 
[2,3]. Finally, models permit analyses 
that extrapolate beyond the limitations 
of a trial’s time constraints, geographic 
setting, and study population [4,5].
    Probably the most important 
contribution of mathematical models 
relies not in the speciﬁ  c point estimates 
they generate, but rather, in the insights 
they provide regarding the likely impact 
of changes in different variables—such 
as access to treatment, sexual behavior, 
natural history of the disease, quality of 
care and adherence—on life expectancy 
and epidemic dynamics. 
    Mathematical Models of HIV 
Treatment
    Mathematical models have been used 
to assess the impact of antiretroviral 
programs on HIV transmission [6]. 
Even though there is no consensus 
on the direction of the effect, many 
of these studies have predicted that 
provision of antiretroviral therapy 
(ART) could have a striking effect on 
transmission when coverage is high [7–
10]. However, these studies also suggest 
that the potential impact of drug-
induced biological changes (reduced 
infectivity or increased duration of 
infection) on HIV transmission is 
likely to be minor compared with the 
potential impact of ART on sexual 
risk behavior. The impact on sexual 
behavior is likely to be greater either 
because availability of treatment 
potentiates prevention efforts or 
because it causes disinhibition and 
increased risk behavior. 
    In a study in   PLoS Medicine  , Rebecca 
Baggaley and colleagues constructed a 
model that describes the impact of ART 
on HIV transmission in developing 
countries, and they chose Malawi to 
apply their model [11]. The authors 
made a number of assumptions in 
constructing their model—for example, 
they assumed that there is only a 
single, standard triple-combination 
therapy regimen, with no second line 
or salvage therapy available for those 
who experience treatment failure. 
They used the model to predict and 
compare the epidemiological impacts 
of alternative strategies for rolling out 
ART (for example, initiating treatment 
at varying stages of disease).
    The authors’ model predicted that 
the unlimited provision of ART, started 
at late-stage infection (AIDS), would 
lead to an increase in HIV prevalence. 
The effect of additionally treating 
patients with earlier infection (pre-
AIDS) would depend on whether 
treated patients changed their sexual 
behavior. The authors concluded 
that one cannot expect the provision 
of ART, at least in high-prevalence 
African epidemics, to have important 
effects on HIV transmission, a ﬁ  nding 
that is consistent with the previous 
studies summarized above.
    Limitations of the New Model
    The authors’ modeling was restricted to 
considering changes in risk behavior by 
those persons with HIV infection who 
initiated ART. They did not consider 
how availability of therapy may lead to 
dramatic changes in risk behavior (in 
either direction) among the far larger 
population of people who are not 
infected, infected but don’t know their 
status, or infected but not eligible for 
therapy.
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    The authors’ decision not to consider 
these effects is understandable given 
their focus on comparing different 
initiation/discontinuation strategies 
for ART, and given the lamentable lack 
of data on population-level changes in 
risk behavior following introduction of 
ART. However, as the work by Mead 
Over and colleagues in India suggests, 
small changes in population-level risk 
behaviors indirectly caused by ART 
are likely to be far more important 
determinants of the epidemic’s 
course than are changes among 
those receiving therapy [10]. Thus, 
we conclude that the key messages 
regarding ART and prevention seem 
to be the following: (1) choice of 
ART initiation, monitoring, and 
discontinuation strategies is unlikely 
to have a major impact on prevention, 
so choose treatment algorithms that 
maximize treatment efﬁ  ciency, and (2) 
focus on how ART implementation can 
be   prevention-enhancing  . To accomplish 
the latter, programs must evaluate 
different strategies to maximize the 
potential positive impact on prevention 
and minimize the potential for 
disinhibition.
    The other important limitation 
of Baggaley and colleagues’ study 
is suggested by the authors in their 
conclusion: “…in reality, scaling up 
programmes is likely to compromise 
quality, meaning higher dropout 
rates, mortality and treatment failure, 
negating the beneﬁ  cial impacts of 
ART, and increasing the rate of drug 
resistance emergence.” Not only does 
the model not capture likely declines 
in quality with increasing scale, it also 
does not appear to adequately capture 
the likely population heterogeneity 
with respect to quality of care and 
patient adherence to treatment. 
    While the model considers four 
different classes of sexual risk behavior 
(i.e., four different levels of sexual 
activity, from high to low), it appears 
to treat quality and adherence as 
parameters that are constant across 
patients and providers. While the 
amount of bias introduced by this 
simpliﬁ  cation will clearly depend on 
the true degree of heterogeneity in 
the population, the highly nonlinear 
relationship between adherence 
and viral suppression suggests 
that the   distribution   of adherence 
in the population is an important 
determinant of average effectiveness, 
not just the mean adherence. Our 
concern about this issue is heightened 
because of our experience in Mexico, 
where we have documented very 
high levels of provider and patient 
heterogeneity [12]. In poorer countries 
with fewer drug choices and in 
those with stronger central control 
over treatment algorithms (such as 
Malawi), there is likely to be far less 
heterogeneity in prescribing practices, 
but poverty and limited infrastructure 
may contribute to even greater 
heterogeneity in drug supply, in patient 
access to treatment, and in adherence. 
  The  Policy  Implications
    Baggaley and colleagues suggest 
that policy makers, in their quest to 
maximize the efﬁ  ciency of treatment, 
need to consider both the likelihood 
that a patient will beneﬁ  t from ART 
(e.g., probability that they will have 
immune reconstitution syndrome) 
and the possibility of reallocating 
treatment from someone in virological 
failure to someone who has not yet 
been able to initiate therapy. If our 
hypotheses are correct, then it is likely 
to be even more important, in order to 
maximize the efﬁ  ciency of treatment, 
to consider the probability that a 
patient will receive care of adequate 
quality, will have consistent access 
to drugs, and will be both willing 
and able to maintain high levels of 
adherence. The next generation of 
models should seek to incorporate 
a more nuanced treatment of these 
issues—but their ability to do so will 
also depend on whether data are 
collected in programs currently being 
scaled up on prescription patterns, 
consistency of drug supply, adherence, 
and duration of viral suppression.
    We have argued that mathematical 
modeling can be very useful for 
informing policy choices, but it is 
important that such an argument 
not be construed to mean that 
mathematical modeling can 
replace data on effectiveness of 
interventions. On the contrary, for 
future modeling exercises to usefully 
inform policy, better data are needed. 
For reasons that are not entirely 
apparent, the scientiﬁ  c community, 
nongovernmental organizations, 
and government ofﬁ  cials have not 
insisted that sufﬁ  ciently rigorous 
data be generated on effectiveness of 
HIV/AIDS interventions as they are 
scaled up. Without even considering 
prevention interventions, the amount 
of information known about how to 
achieve high rates of ART adherence 
in developing countries, to take 
just one example, is nowhere near 
commensurate with either the size of 
the problem or the resources being 
committed to address the problem. If 
we don’t take advantage of the current 
scale-up of interventions to collect data 
on which approaches work and which 
ones don’t (thus reducing the depth of 
our ignorance), it will be impossible to 
convince people to continue to fund 
such programs. And if we don’t ﬁ  gure 
out how to implement ART in a way 
that greatly potentiates the effectiveness 
of prevention, the costs of care in the 
future will likely outstrip even the 
most optimistic projections of resource 
availability.   
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